366 related articles for article (PubMed ID: 31900174)
1. Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study.
Dougados M; van der Heijde D; Tsai WC; Saaibi D; Marshall L; Jones H; Pedersen R; Vlahos B; Tarallo M
Health Qual Life Outcomes; 2020 Jan; 18(1):4. PubMed ID: 31900174
[TBL] [Abstract][Full Text] [Related]
2. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.
van der Heijde D; Joshi A; Pangan AL; Chen N; Betts K; Mittal M; Bao Y
Rheumatology (Oxford); 2016 Jan; 55(1):80-8. PubMed ID: 26316575
[TBL] [Abstract][Full Text] [Related]
3. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
[TBL] [Abstract][Full Text] [Related]
4. Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2.
Navarro-Compán V; Ramiro S; Deodhar A; Mease PJ; Rudwaleit M; de la Loge C; Fleurinck C; Taieb V; Mørup MF; Massow U; Kay J; Magrey M
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38599650
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
[TBL] [Abstract][Full Text] [Related]
6. Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis.
Osterhaus JT; Purcaru O
Arthritis Res Ther; 2014 Aug; 16(4):R164. PubMed ID: 25099160
[TBL] [Abstract][Full Text] [Related]
7. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results.
Deodhar AA; Mease PJ; Rahman P; Navarro-Compán V; Strand V; Hunter T; Bolce R; Leon L; Lauzon S; Marzo-Ortega H
BMC Rheumatol; 2021 Sep; 5(1):35. PubMed ID: 34538257
[TBL] [Abstract][Full Text] [Related]
8. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of etanercept in patients from Latin America, Central Europe and Asia with early non-radiographic axial spondyloarthritis.
Wei JC; Tsai WC; Citera G; Kotak S; Llamado L
Int J Rheum Dis; 2018 Jul; 21(7):1443-1451. PubMed ID: 27863065
[TBL] [Abstract][Full Text] [Related]
10. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
Kilic E; Kilic G; Akgul O; Ozgocmen S
Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
Sieper J; van der Heijde D; Dougados M; Mease PJ; Maksymowych WP; Brown MA; Arora V; Pangan AL
Ann Rheum Dis; 2013 Jun; 72(6):815-22. PubMed ID: 22772328
[TBL] [Abstract][Full Text] [Related]
12. The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.
Lubrano E; Perrotta FM; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
J Rheumatol; 2018 Feb; 45(2):195-201. PubMed ID: 29419448
[TBL] [Abstract][Full Text] [Related]
13. Clinimetric properties of the ASAS health index in a cohort of Italian patients with axial spondyloarthritis.
Di Carlo M; Lato V; Carotti M; Salaffi F
Health Qual Life Outcomes; 2016 May; 14():78. PubMed ID: 27188166
[TBL] [Abstract][Full Text] [Related]
14. Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial.
Deodhar A; Mease P; Rahman P; Navarro-Compán V; Marzo-Ortega H; Hunter T; Sandoval D; Kronbergs A; Leon L; Shan M; Leung A; De Vlam K; Strand V
Rheumatol Ther; 2021 Mar; 8(1):135-150. PubMed ID: 33284423
[TBL] [Abstract][Full Text] [Related]
15. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
[TBL] [Abstract][Full Text] [Related]
16. Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis.
Dougados M; Wood E; Gossec L; Dubanchet A; Logeart I; van der Heijde D
J Rheumatol; 2015 Dec; 42(12):2361-8. PubMed ID: 26568588
[TBL] [Abstract][Full Text] [Related]
17. Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis.
Krabbe S; Glintborg B; Østergaard M; Hetland ML
Scand J Rheumatol; 2019 Mar; 48(2):128-132. PubMed ID: 30102111
[TBL] [Abstract][Full Text] [Related]
18. Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial.
Rusman T; van der Weijden M; Nurmohamed MT; van Denderen CJ; Landewé R; Bet PM; Bijl CV; van der Laken CJ; van der Horst-Bruinsma IE
Scand J Rheumatol; 2023 Mar; 52(2):137-141. PubMed ID: 35543102
[TBL] [Abstract][Full Text] [Related]
19. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
20. Relationship between psychiatric status, self-reported outcome measures, and clinical parameters in axial spondyloarthritis.
Kilic G; Kilic E; Ozgocmen S
Medicine (Baltimore); 2014 Dec; 93(29):e337. PubMed ID: 25546683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
